Use of GLP-1 analogues [49], SGLT-2 inhibitors [50, 51], and to some extent DPP-4 inhibitors [52, 53] has been shown to induce weight loss and should be considered as add-on to metformin in obese T2DM patients. Here, SLC5A2 is linked to type 2 diabetes mellitus.